Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Cancer Gene Ther. 2014 Dec 12;22(1):1–8. doi: 10.1038/cgt.2014.58

Figure 3.

Figure 3

MRI Assessment of tumor volume of mice with U87MG glioblastoma treated with AAVrh.10BevMab or control. U87MG and AAVrh.10BevMab was administered simultaneously (A,B) or 6 days after xenograft (C,D). In A and C, arrows indicate site of tumor on representative coronal image of striatum. Each coronal MRI image corresponds to site of xenograft implantation in four distinct mice. A. MRI, PBS-treated control mice (n=4) and AAVrh.10BevMab-treated mice (n=4). The scans were done at 18 days after U87MG implantation B. Quantification of tumor volumes (from multiple coronal MRI images of whole brain), PBS-treated control (n=4) vs AAVrh.10BevMab-treated mice (n=4) at 18 days. C. MRI, PBS-treated control mice (n=4) and AAVrh.10BevMab post-xenograft treated mice (n=4). The scans were done at 20 days after U87MG implantation D. Quantification of tumor volumes in PBS vs post-xenograft treated mice (n=4 per group) at 20 days.